Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
229
Assessments of global and cognitive function of Severe AD patients
Assessment of behavior and performance on Activity of Daily Living in severe AD patients
Assessment of caregiver burden
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Northport, Alabama, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Sun City, Arizona, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
San Francisco, California, United States
Unnamed facility
Santa Monica, California, United States
Unnamed facility
Torrance, California, United States
Unnamed facility
Denver, Colorado, United States
Unnamed facility
Fort Lauderdale, Florida, United States
Unnamed facility
Fort Myers, Florida, United States
...and 32 more locations